Strategies to manage hepatitis C virus (HCV) disease burden
Open Access
- 8 April 2014
- journal article
- research article
- Published by Wiley in Journal of Viral Hepatitis
- Vol. 21 (s1), 60-89
- https://doi.org/10.1111/jvh.12249
Abstract
The number of hepatitis C virus (HCV) infections is projected to decline while those with advanced liver disease will increase. A modeling approach was used to forecast two treatment scenarios: (i) the impact of increased treatment efficacy while keeping the number of treated patients constant and (ii) increasing efficacy and treatment rate. This analysis suggests that successful diagnosis and treatment of a small proportion of patients can contribute significantly to the reduction of disease burden in the countries studied. The largest reduction in HCV‐related morbidity and mortality occurs when increased treatment is combined with higher efficacy therapies, generally in combination with increased diagnosis. With a treatment rate of approximately 10%, this analysis suggests it is possible to achieve elimination of HCV (defined as a >90% decline in total infections by 2030). However, for most countries presented, this will require a 3–5 fold increase in diagnosis and/or treatment. Thus, building the public health and clinical provider capacity for improved diagnosis and treatment will be critical.Keywords
Funding Information
- Gilead Sciences
This publication has 41 references indexed in Scilit:
- The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigmJournal of Viral Hepatitis, 2014
- Chronic hepatitis C virus (HCV) disease burden and cost in the United StatesHepatology, 2012
- Predicted Effects of Treatment for HCV Infection Vary Among European CountriesGastroenterology, 2012
- Telaprevir for Previously Untreated Chronic Hepatitis C Virus InfectionThe New England Journal of Medicine, 2011
- Aging of Hepatitis C Virus (HCV)-Infected Persons in the United States: A Multiple Cohort Model of HCV Prevalence and Disease ProgressionGastroenterology, 2010
- Peginterferon Alfa-2b or Alfa-2a with Ribavirin for Treatment of Hepatitis C InfectionThe New England Journal of Medicine, 2009
- Telaprevir and Peginterferon with or without Ribavirin for Chronic HCV InfectionThe New England Journal of Medicine, 2009
- Telaprevir with Peginterferon and Ribavirin for Chronic HCV Genotype 1 InfectionThe New England Journal of Medicine, 2009
- Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients: A randomized trialHepatology, 2007
- Impact of weight-based ribavirin with peginterferon alfa-2b in african americans with hepatitis C virus genotype 1Hepatology, 2007